Andrew Chan

13.6k total citations
245 papers, 5.7k citations indexed

About

Andrew Chan is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Andrew Chan has authored 245 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Pathology and Forensic Medicine, 56 papers in Oncology and 46 papers in Immunology. Recurrent topics in Andrew Chan's work include Multiple Sclerosis Research Studies (117 papers), Polyomavirus and related diseases (37 papers) and Peripheral Neuropathies and Disorders (30 papers). Andrew Chan is often cited by papers focused on Multiple Sclerosis Research Studies (117 papers), Polyomavirus and related diseases (37 papers) and Peripheral Neuropathies and Disorders (30 papers). Andrew Chan collaborates with scholars based in Germany, Switzerland and United States. Andrew Chan's co-authors include Ralf Gold, Robert Hoepner, Tim Magnus, Kerstin Hellwig, Aiden Haghikia, Klaus V. Toyka, Anke Salmen, Ralf Gold, Ingo Kleiter and Karon E. MacLean and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Andrew Chan

231 papers receiving 5.6k citations

Peers

Countries citing papers authored by Andrew Chan

Since Specialization

Citations

This map shows the geographic impact of Andrew Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Chan more than expected).

Fields of papers citing papers by Andrew Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Chan. The network helps show where Andrew Chan may publish in the future.

Co-authorship network of co-authors of Andrew Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Chan. A scholar is included among the top collaborators of Andrew Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Chan. Andrew Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis 2025 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), (unknown), (unknown), Maria‐Eleftheria Evangelopoulos, Aleksandra Maleska Maceski, (unknown), Jens Kühle, (unknown), (unknown), (unknown), Andrew Chan, Vincent Pernet	3
2	Iron( ii )-catalysed tyrosinase crosslinked hyaluronic acid hydrogel for the controlled release of human antibodies 2025 ·Journal of Materials Chemistry B ·(unknown), Martin Pravda, (unknown), (unknown), (unknown), (unknown), Andrew Chan, Vincent Pernet, Vladimı́r Velebný	1
3	Sex differences in multiple sclerosis relapse presentation and outcome: a retrospective, monocentric study of 134 relapse events 2024 ·Therapeutic Advances in Neurological Disorders ·(unknown), (unknown), (unknown), Franca Wagner, (unknown), (unknown), (unknown), Piotr Radojewski, Roland Wiest, Andrew Chan, Robert Hoepner, Anke Salmen	2
4	Sex‐ and age‐related shift of relapse phenotypes in a cohort of relapsing multiple sclerosis patients: Post hoc analysis from the OPERA phase 3 trials 2024 ·European Journal of Neurology ·(unknown), Robert Hoepner, (unknown), Andrew Chan, Anke Salmen	1
5	Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies 2023 ·SHILAP Revista de lepidopterología ·(unknown), Angalee Nadesalingam, Andrew Chan, Peter Smith, Minna Paloniemi, Diego Cantoni, (unknown), (unknown), George Carnell, Javier Castillo‐Olivares, Nigel Temperton, Barbara Blacklaws, Jonathan L. Heeney, Helen Baxendale	3
6	The future of diagnosis in clinical neurosciences: Comparing multiple sclerosis and schizophrenia 2023 ·European Psychiatry ·Błażej Misiak, Jerzy Samochowiec, Krzysztof Kowalski, Wolfgang Gäebel, Claudio L. Bassetti, Andrew Chan, Philip Gorwood, Sergi Papiol, Geert Dom, Umberto Volpe, Agata Szulc, Tamás Kurimay, Hilkka Kärkkäinen, (unknown), (unknown), Andrea Fiorillo, Peter Falkai	16
7	Development of an Open-source and Lightweight Sensor Recording Software System for Conducting Biomedical Research: Technical Report 2023 ·JMIR Formative Research ·(unknown), (unknown), Narayan Schütz, (unknown), (unknown), (unknown), Kaspar Schindler, Paul Krack, Roland Wiest, Andrew Chan, Tobias Nef, Stephan M. Gerber	3
8	Nogo-A antibody delivery through the olfactory mucosa mitigates experimental autoimmune encephalomyelitis in the mouse CNS 2023 ·Cell Death Discovery ·Vincent Pernet, Sandrine Joly, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ludovico Silvestri, Francesco S. Pavone, Martino Calamai, Katharina Schindowski, Andrew Chan	12
9	Modelling MOG antibody-associated disorder and neuromyelitis optica spectrum disorder in animal models: Spinal cord manifestations 2023 ·Multiple Sclerosis and Related Disorders ·(unknown), (unknown), (unknown), (unknown), Christopher Linington, Andrew Chan, Jeffrey L. Bennett, Robert Hoepner, Volker Enzmann, Anke Salmen	4
10	Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis 2022 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), (unknown), (unknown), Robert Hoepner, (unknown), (unknown), (unknown), Mathias Abegg, Christopher Linington, Anthony Shock, Babak Boroojerdi, Peter Kießling, Bryan Smith, Volker Enzmann, Andrew Chan, Anke Salmen	18
11	Multidimensional phenotyping of the post‐COVID‐19 syndrome: A Swiss survey study 2022 ·CNS Neuroscience & Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Lea Weber, (unknown), Andrew Chan, Claudio L. Bassetti, Anke Salmen, Robert Hoepner	15
12	Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients 2022 ·Vaccines ·(unknown), Robert Hoepner, (unknown), Stephen L. Leib, Franziska Suter‐Riniker, (unknown), (unknown), Andrew Chan, Anke Salmen, Christian P. Kamm	2
13	The Real-World Experiences of Persons With Multiple Sclerosis During the First COVID-19 Lockdown: Application of Natural Language Processing 2022 ·JMIR Medical Informatics ·(unknown), (unknown), Andrew Chan, Christian P. Kamm, Chloé Sieber, (unknown), Stephanie Rodgers, Caroline Pot, Jürg Kesselring, Anke Salmen, (unknown), Pasquale Calabrese, Zina‐Mary Manjaly, Claudio Gobbi, Chiara Zecca, Sebastian Walther, Katharina Stegmayer, Robert Hoepner, Milo A. Puhan, Viktor von Wyl	2
14	Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients 2022 ·Multiple Sclerosis Journal ·(unknown), Franca Wagner, (unknown), (unknown), Roland Wiest, (unknown), Andrew Chan, Anke Salmen, Robert Hoepner	11
15	Multiple sclerosis as a model to investigate SARS‐CoV‐2 effect on brain atrophy 2022 ·CNS Neuroscience & Therapeutics ·Michael Rebsamen, (unknown), Piotr Radojewski, (unknown), Andrew Chan, Roland Wiest, Anke Salmen, Christian Rummel, Robert Hoepner	4
16	Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies 2021 ·Therapeutic Advances in Neurological Disorders ·(unknown), (unknown), (unknown), (unknown), Franziska Suter‐Riniker, Stephen L. Leib, Andrew Chan, Cédric Hirzel, Robert Hoepner, Anke Salmen	4
17	Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study 2021 ·Therapeutic Advances in Neurological Disorders ·Panagiotis Chaloulos-Iakovidis, Franca Wagner, Lea Weber, (unknown), Andrew Chan, Anke Salmen, (unknown), Robert Hoepner	4
18	c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis 2020 ·Cells ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Anke Salmen, Andrew Chan, Robert Hoepner	14
19	Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort 2020 ·CNS Neuroscience & Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Roland Wiest, Franca Wagner, (unknown), Mathias Abegg, Michael P. Horn, Sandra Bigi, Andrew Chan, Robert Hoepner, Anke Salmen	8
20	Age‐dependent variation of female preponderance across different phenotypes of multiple sclerosis: A retrospective cross‐sectional study 2018 ·CNS Neuroscience & Therapeutics ·(unknown), Anke Salmen, (unknown), (unknown), Christian P. Kamm, (unknown), (unknown), (unknown), (unknown), Leonidas Stefanis, Andrew Chan, Maria‐Eleftheria Evangelopoulos, Robert Hoepner	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact